• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness

tetano

Editor, Senior Moderator
Immunity. 2017 May 16;46(5):875-890.e6. doi: 10.1016/j.immuni.2017.04.025.
[h=1]Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness.[/h] Galani IE[SUP]1[/SUP], Triantafyllia V[SUP]1[/SUP], Eleminiadou EE[SUP]1[/SUP], Koltsida O[SUP]1[/SUP], Stavropoulos A[SUP]1[/SUP], Manioudaki M[SUP]1[/SUP], Thanos D[SUP]2[/SUP], Doyle SE[SUP]3[/SUP], Kotenko SV[SUP]4[/SUP], Thanopoulou K[SUP]1[/SUP], Andreakos E[SUP]5[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Lambda interferons (IFNλs) or type III IFNs share homology, expression patterns, signaling cascades, and antiviral functions with type I IFNs. This has complicated the unwinding of their unique non-redundant roles. Through the systematic study of influenza virus infection in mice, we herein show that IFNλs are the first IFNs produced that act at the epithelial barrier to suppress initial viral spread without activating inflammation. If infection progresses, type I IFNs come into play to enhance viral resistance and induce pro-inflammatory responses essential for confronting infection but causing immunopathology. Central to this are neutrophils which respond to both cytokines to upregulate antimicrobial functions but exhibit pro-inflammatory activation only to type I IFNs. Accordingly, Ifnlr1[SUP]-/-[/SUP] mice display enhanced type I IFN production, neutrophilia, lung injury, and lethality, while therapeutic administration of PEG-IFNλ potently suppresses these effects. IFNλs therefore constitute the front line of antiviral defense in the lung without compromising host fitness.
Copyright ? 2017 Elsevier Inc. All rights reserved.


PMID: 28514692 DOI: 10.1016/j.immuni.2017.04.025
 
Immunity. 2017 May 16;46(5):768-770. doi: 10.1016/j.immuni.2017.04.027.
[h=1]You Can Breathe Easy: IFNλ Handles Flu without Triggering a Damaging Inflammatory Response.[/h] Robinson BA[SUP]1[/SUP], Nice TJ[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Type III interferon (IFNλ) and type I IFN (IFNα/β) have overlapping antiviral activities in the lung. In this issue of Immunity, Galani et al. (2017) identify a critical early role for IFNλ, not shared by IFNα/β, in protection of the lung following influenza virus infection.
Copyright ? 2017 Elsevier Inc. All rights reserved.


PMID: 28514682 DOI: 10.1016/j.immuni.2017.04.027
 
Back
Top Bottom